Bill Accomando

Bill Accomando, PhD has a diverse work experience in the fields of biotechnology, cancer research, and epidemiology. Bill has served as a Principal Scientist at Fate Therapeutics Inc, where they developed bioanalytical assays for the characterization and clinical lot release of cellular immunotherapies. Prior to this, they worked as a Senior Scientist at the same company.

Before joining Fate Therapeutics Inc, Accomando held positions at Tocagen, where they conducted research on drug efficacy and mechanisms of action in cancer gene therapies. Bill also worked at the German Cancer Research Center and German Cancer Consortium, where they conducted epigenetic epidemiological studies of colon and prostate cancer. Accomando's experience at Harvard School of Public Health involved the development of next-generation sequencing library preparation methodologies and applying them to human blood samples.

Accomando's educational background includes a role as a Graduate Research Assistant at Brown University, where they focused on epigenetic biomarkers, cancer epigenetics, and immunology. Bill also conducted research as a Research Assistant at Dartmouth College, investigating AMP activated kinase signaling pathways.

Overall, Accomando's work experience showcases their expertise in developing bioanalytical assays, conducting cancer research, and performing epidemiological studies.

Bill Accomando, PhD, obtained their Bachelor of Arts degree in Biology from Dartmouth College from 2003 to 2007. From 2008 to 2013, they pursued their Ph.D. in Pathobiology at Brown University.